https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725

The patient’s report was accurate.

Ivermectin is used as a strong anti-inflammatory esp for scabies and lice resistant to other interventions.

Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016 Sep 15;22(9):13030/qt1kq4p7pp. PMID: 28329606.

see also

Mathachan SR, Sardana K, Khurana A. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatol Online J. 2021;12(4):500-514. Published 2021 Jul 14. doi:10.4103/idoj.idoj_298_21

Ivermectin is a broad-spectrum antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial, and anti-tumor effects. In this review, we discuss the history, pharmacology, multimodal actions, indications in dermatology and tropical medicine, therapeutic and prophylactic use of ivermectin in COVID-19, safety, adverse effects, special considerations, and drug interactions of ivermectin.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

https://news.uthscsa.edu/team-discovers-novel-root-cause-of-tau-induced-neurodegeneration-2/

	Elsevier Psychiatry ⁦‪@els_psychiatry‬⁩ Schizophrenia Research special Issue features commentaries by 45 prominent schizophrenia international researchers, expressing their perspectives on how the century-old concept of schizophrenia should be updated/reinvented given the advances in the field spkl.io/60174R9qZ pic.twitter.com/Eh9YKLjmer 4/20/22, 7:30 AM

	American Foundation for Suicide Prevention ⁦‪@afspnational‬⁩ We’re less than 100 days out from launch of the 988 mental health crisis hotline. State and municipal leaders must prepare for the full continuum of care: • Someone to call • Someone to show up • Someplace to go See our readiness plan: wellbeingtrust.org/uncategorized/… pic.twitter.com/xb4EUPRQn6 4/19/22, 1:54 PM

	American Psychiatric Association ⁦‪@APAPsychiatric‬⁩ With the launch of 988 less than 100 days away, there remains much to be done to get ready. Learn more about 988 and our CEO Alliance for Mental Health plan. More info: ow.ly/TxYW50ILV5Z pic.twitter.com/CvjLM8TaX3 4/18/22, 6:50 PM

	Tom Insel, MD ⁦‪@thomasinselmd‬⁩ In terms of life expectancy, Americans with #mentalillness are living in the early 1920s. We need to ensure people with SMI will get medical care that ensures a normal life expectancy. pic.twitter.com/VrzYJahBZ9 4/14/22, 8:22 PM

	Steven Chan, MD MBA ⁦‪@StevenChanMD‬⁩ In the Journal of Current Psychiatry Reports, ⁦‪@StevenChanMD‬⁩ & colleagues discuss computer-assisted cognitive-behavior therapy and mobile apps for depression and anxiety: lttr.ai/vbWh #telepsychiatry #telemedicine #mentalhealth pic.twitter.com/jygMBxcYIF 4/12/22, 6:17 PM